140 related articles for article (PubMed ID: 31126725)
1. Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
Roy S; Loblaw A; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Helou J; Zhang L; Mamedov A; Deabreu A; Quon HC
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):621-629. PubMed ID: 31126725
[TBL] [Abstract][Full Text] [Related]
2. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial.
Kim DN; Straka C; Cho LC; Lotan Y; Yan J; Kavanagh B; Raben D; Cooley S; Brindle J; Xie XJ; Pistenmaa D; Timmerman R
Pract Radiat Oncol; 2017; 7(1):e43-e49. PubMed ID: 27637137
[TBL] [Abstract][Full Text] [Related]
3. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
Jiang NY; Dang AT; Yuan Y; Chu FI; Shabsovich D; King CR; Collins SP; Aghdam N; Suy S; Mantz CA; Miszczyk L; Napieralska A; Namysl-Kaletka A; Bagshaw H; Prionas N; Buyyounouski MK; Jackson WC; Spratt DE; Nickols NG; Steinberg ML; Kupelian PA; Kishan AU
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):628-636. PubMed ID: 31276777
[TBL] [Abstract][Full Text] [Related]
4. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
Hauck CR; Ye H; Chen PY; Gustafson GS; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):108-114. PubMed ID: 28586946
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
9. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer.
Mehta NH; Kamrava M; Wang PC; Steinberg M; Demanes J
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):729-33. PubMed ID: 23582852
[TBL] [Abstract][Full Text] [Related]
13. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator.
Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
15. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
Kataria S; Koneru H; Guleria S; Danner M; Ayoob M; Yung T; Lei S; Collins BT; Suy S; Lynch JH; Kole T; Collins SP
Front Oncol; 2017; 7():157. PubMed ID: 28791252
[TBL] [Abstract][Full Text] [Related]
17. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
Levin-Epstein RG; Jiang NY; Wang X; Upadhyaya SK; Collins SP; Suy S; Aghdam N; Mantz C; Katz AJ; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas N; Bagshaw H; Buyyounouski MK; Cao M; Agazaryan N; Dang A; Yuan Y; Kupelian PA; Zaorsky NG; Spratt DE; Mohamad O; Feng FY; Mahal BA; Boutros PC; Kishan AU; Juarez J; Shabsovich D; Jiang T; Kahlon S; Patel A; Patel J; Nickols NG; Steinberg ML; Fuller DB; Kishan AU
Radiother Oncol; 2021 Jan; 154():207-213. PubMed ID: 33035622
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.
King CR; Freeman D; Kaplan I; Fuller D; Bolzicco G; Collins S; Meier R; Wang J; Kupelian P; Steinberg M; Katz A
Radiother Oncol; 2013 Nov; 109(2):217-21. PubMed ID: 24060175
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
